Skip to main content
. 2019 Oct 3;14(1):139–148. doi: 10.1093/ckj/sfz120

Table 7.

Preventive treatments for FSGS recurrence reported in literature

Reference Number of patients (risk factor for recurrence) Preventive treatment (concomitant therapies) Recurrence in treated patients (%) Recurrence in control group
Auñón 12 (hypoalbuminaemia at baseline)

  • Rituximab, two doses of 1 g

  • (+ plasmapheresis in two patients)

 50

  • 40.9%

  • ‘High-risk’ control group
Alasfar et al. [20] 37 (≥2 risk factors)

  • Rituximab, one or two doses of 375 mg/m2

  • (+ plasmapheresis in 28 patients)

 62

  • 51%

  • ‘Low-risk’ control group
Fornoni et al. [17] 27 (young age, rapid progression) Rituximab, one dose of 375 mg/m2 26

  • 64%

  • Historical

  • control group
Gohh et al. [35] 10 (previous graft lost due to recurrence or rapid progression) Plasmapheresis 30 No control group
Park et al. [19] 9

  • Plasmapheresis

  • (+ rituximab, one or two doses of 375 mg/m2 in five patients)

 22 27.7%
Audard et al. [18] 4 (previous graft lost due to recurrence)

  • Rituximab, one or two doses of 375 mg/m2

  • (+ plasmapheresis in two patients)

 0 No control group